Invention Grant
US08546435B2 Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
有权
具有改善的受体活性和生物利用度性质的三唑衍生物作为生长激素促分泌素受体的生长素释放肽拮抗剂
- Patent Title: Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
- Patent Title (中): 具有改善的受体活性和生物利用度性质的三唑衍生物作为生长激素促分泌素受体的生长素释放肽拮抗剂
-
Application No.: US13235116Application Date: 2011-09-16
-
Publication No.: US08546435B2Publication Date: 2013-10-01
- Inventor: Babette Aicher , Gilbert Mueller , Klaus Paulini , Lars Blumenstein , Peter Schmidt , Matthias Gerlach , Michael Teifel , Jean Martinez , Jean-Alain Fehrentz , Anne-Laure Blayo
- Applicant: Babette Aicher , Gilbert Mueller , Klaus Paulini , Lars Blumenstein , Peter Schmidt , Matthias Gerlach , Michael Teifel , Jean Martinez , Jean-Alain Fehrentz , Anne-Laure Blayo
- Applicant Address: DE Frankfurt am Main FR Paris FR Montpellier FR Montpellier
- Assignee: AEterna Zentaris GmbH,Centre National de la Recherche Scientifique,University of Montpellier I,University of Montpellier II
- Current Assignee: AEterna Zentaris GmbH,Centre National de la Recherche Scientifique,University of Montpellier I,University of Montpellier II
- Current Assignee Address: DE Frankfurt am Main FR Paris FR Montpellier FR Montpellier
- Agency: Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P.
- Priority: EP10177105 20100916
- Main IPC: A61K31/41
- IPC: A61K31/41 ; C07D249/08

Abstract:
The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).
Public/Granted literature
Information query